Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intel applies nanotechnology expertise to disease detection:

This article was originally published in Clinica

Executive Summary

Intel has teamed up with a US institution to apply its expertise in nanotechnology to develop improved methods of studying, diagnosing and preventing cancer. The company is building an Intel Raman bioanalyser system at the Fred Hutchinson Cancer Research Center, in Seattle, to determine whether the technology, previously used to detect microscopic imperfections on silicon chips, can also detect subtle traces of disease. The instrument beams lasers onto medical samples, such as serum, to create images that reveal the chemical structure of molecules. The research could lead to a new era of molecular diagnostics and improved methods of early disease detection, the company said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel